Literature DB >> 11418637

Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter.

V Deffrennes1, J Vedrenne, M C Stolzenberg, J Piskurich, G Barbieri, J P Ting, D Charron, C Alcaïde-Loridan.   

Abstract

In melanoma cell lines, two different patterns of MHC class II expression have been described, either an IFN gamma-inducible expression of HLA-DR and HLA-DP, with a faint or null expression of HLA-DQ, resembling that described for melanocytes, or a constitutive expression, i.e., IFN-gamma independent, of all three HLA-D isotypes. As this latter phenotype has been associated with a more rapid progression of melanoma tumors, we have analyzed in different melanoma cell lines the molecular mechanisms leading to this abnormal pattern of MHC class II expression. In agreement with the evidence of a coordinate transcription of the HLA-D genes in these cell lines, we have shown the constitutive expression of CIITA (class II transactivator) transcripts, CIITA being known as the master switch of MHC class II expression. Unexpectedly, these transcripts initiate from promoter III of the CIITA gene, a promoter that is mainly used constitutively in B lymphocytes. This expression was further shown to occur through factor(s) acting on the enhancer located upstream of CIITA promoter III, which was previously described in epithelioid cells as an IFN-gamma-response sequence. The hypothesis of a general abnormality of the IFN-gamma transduction pathway was dismissed. Constitutive transcription of CIITA from promoter III having been observed in unrelated melanoma cell lines, we propose the hypothesis that this phenomenon might not be a random event, but could be linked to the neoplasic state of the melanoma cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11418637     DOI: 10.4049/jimmunol.167.1.98

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Contrasting effects of IFNα on MHC class II expression in professional vs. nonprofessional APCs: Role of CIITA type IV promoter.

Authors:  Laura Pisapia; Giovanna Del Pozzo; Pasquale Barba; Alessandra Citro; Paul E Harris; Antonella Maffei
Journal:  Results Immunol       Date:  2012-09-27

Review 2.  Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.

Authors:  Margaret L Axelrod; Rebecca S Cook; Douglas B Johnson; Justin M Balko
Journal:  Clin Cancer Res       Date:  2018-11-21       Impact factor: 12.531

Review 3.  Immune and molecular correlates in melanoma treated with immune checkpoint blockade.

Authors:  Elizabeth H Byrne; David E Fisher
Journal:  Cancer       Date:  2017-06-01       Impact factor: 6.860

4.  Hexim1 sequesters positive transcription elongation factor b from the class II transactivator on MHC class II promoters.

Authors:  Jiri Kohoutek; Dalibor Blazek; B Matija Peterlin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-06       Impact factor: 11.205

5.  Splicing defect in RFXANK results in a moderate combined immunodeficiency and long-duration clinical course.

Authors:  Thomas Prod'homme; Benjamin Dekel; Giovanna Barbieri; Barbara Lisowska-Grospierre; Rina Katz; Dominique Charron; Catherine Alcaide-Loridan; Shimon Pollack
Journal:  Immunogenetics       Date:  2003-10-22       Impact factor: 2.846

6.  Distinct MHC gene expression patterns during progression of melanoma.

Authors:  Yan Degenhardt; Jia Huang; Joel Greshock; Galene Horiates; Katherine Nathanson; Xiaolu Yang; Meenhard Herlyn; Barbara Weber
Journal:  Genes Chromosomes Cancer       Date:  2010-02       Impact factor: 5.006

7.  Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma.

Authors:  Jennifer Nguyen; Richard Bernert; Kevin In; Paul Kang; Noemi Sebastiao; Chengcheng Hu; K Taraszka Hastings
Journal:  Melanoma Res       Date:  2016-04       Impact factor: 3.599

8.  Identification of bacteria-derived HLA-bound peptides in melanoma.

Authors:  Shelly Kalaora; Adi Nagler; Deborah Nejman; Michal Alon; Chaya Barbolin; Eilon Barnea; Steven L C Ketelaars; Kuoyuan Cheng; Kevin Vervier; Noam Shental; Yuval Bussi; Ron Rotkopf; Ronen Levy; Gil Benedek; Sophie Trabish; Tali Dadosh; Smadar Levin-Zaidman; Leore T Geller; Kun Wang; Polina Greenberg; Gal Yagel; Aviyah Peri; Garold Fuks; Neerupma Bhardwaj; Alexandre Reuben; Leandro Hermida; Sarah B Johnson; Jessica R Galloway-Peña; William C Shropshire; Chantale Bernatchez; Cara Haymaker; Reetakshi Arora; Lior Roitman; Raya Eilam; Adina Weinberger; Maya Lotan-Pompan; Michal Lotem; Arie Admon; Yishai Levin; Trevor D Lawley; David J Adams; Mitchell P Levesque; Michal J Besser; Jacob Schachter; Ofra Golani; Eran Segal; Naama Geva-Zatorsky; Eytan Ruppin; Pia Kvistborg; Scott N Peterson; Jennifer A Wargo; Ravid Straussman; Yardena Samuels
Journal:  Nature       Date:  2021-03-17       Impact factor: 49.962

9.  High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma.

Authors:  Carsten Linnemann; Marit M van Buuren; Laura Bies; Els M E Verdegaal; Remko Schotte; Jorg J A Calis; Sam Behjati; Arno Velds; Henk Hilkmann; Dris El Atmioui; Marten Visser; Michael R Stratton; John B A G Haanen; Hergen Spits; Sjoerd H van der Burg; Ton N M Schumacher
Journal:  Nat Med       Date:  2014-12-22       Impact factor: 53.440

10.  On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases.

Authors:  M R Bernsen; L Håkansson; B Gustafsson; L Krysander; B Rettrup; D Ruiter; A Håkansson
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.